Edgewood Oncology Inc.
Edgewood Oncology is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients with the greatest unmet medical needs, focusing on BTX-A51, a multi-kinase inhibitor targeting master regulators of cancer.
Industries
Nr. of Employees
small (1-50)
Edgewood Oncology Inc.
207 Washington Street, P.O. Box 471012, Brookline MA 02447
Patents
Products
Investigational small-molecule multi-kinase inhibitor (CK1α, CDK7, CDK9)
An investigational oral small-molecule inhibitor that co-targets CK1α and transcriptional kinases CDK7 and CDK9 to decrease oncogene expression, stabilize p53 and induce apoptosis; advanced in preclinical studies and early-phase clinical trials for hematologic malignancies and genetically-defined solid tumors.
Investigational small-molecule multi-kinase inhibitor (CK1α, CDK7, CDK9)
An investigational oral small-molecule inhibitor that co-targets CK1α and transcriptional kinases CDK7 and CDK9 to decrease oncogene expression, stabilize p53 and induce apoptosis; advanced in preclinical studies and early-phase clinical trials for hematologic malignancies and genetically-defined solid tumors.
Services
Partnerships to enable investigator-initiated clinical trials through provision of investigational compound and scientific support.
Partnerships to enable investigator-initiated clinical trials through provision of investigational compound and scientific support.
Expertise Areas
- Oncology drug discovery
- Translational oncology
- Early‑phase clinical development
- Biomarker-driven clinical development
Key Technologies
- Small-molecule kinase inhibition
- CK1α inhibition
- CDK7 inhibition
- CDK9 inhibition
News & Updates
Efficacy data from a study of BTX-A51 in liposarcoma models.
First patient dosed in a Phase 1 study of BTX-A51 in liposarcoma.
Preclinical data to be presented at AACR Annual Meeting 2025.
First patients dosed in a Phase 2a study of BTX-A51 in breast cancer.
Positive efficacy data from a study of BTX-A51 in liposarcoma models.
Series A financing to support development of BTX-A51.
Efficacy data from a study of BTX-A51 in liposarcoma models.
First patient dosed in a Phase 1 study of BTX-A51 in liposarcoma.
Preclinical data to be presented at AACR Annual Meeting 2025.
First patients dosed in a Phase 2a study of BTX-A51 in breast cancer.
Positive efficacy data from a study of BTX-A51 in liposarcoma models.
Series A financing to support development of BTX-A51.